Q.01

Why did the FDA warn Amgen about Vectibix?

I couldn't confirm why the FDA warned Amgen about Vectibix (panitumumab): I couldn't find the letter on FDA's website or in the warning letter records I can search, so I can't give you its findings from the official text.

  • FDA's warning letters listing: I opened the public listing, where the newest postings are dated 27 October 2026. It had no entry for Amgen. (FDA Warning Letters)
  • Prescription drug promotion letters: FDA's page that links to letters about drug advertising and promotion didn't show an Amgen or Vectibix entry. I also tried to open FDA's page of 2026 untitled letters, but it returned "not found". (Warning Letters and Notice of Violation Letters to Pharmaceutical Companies)
  • News coverage: News reports dated 27 October 2026 say FDA sent Amgen a warning letter about Vectibix. FDA often posts warning letters on its site some time after they are issued, which may be why it isn't there yet. I haven't relied on those reports for the reasons, because they aren't an official FDA source and I couldn't check them against the letter.

The Vectibix records I did find on FDA's site are approval letters and prescribing information, not enforcement letters (2013 supplement approval letter, 2025 label). Once FDA posts the letter, I can go through what it says was wrong and what it asks Amgen to do.

Approach: I searched the FDA warning, response and closeout letters I can access, then FDA's own pages listing warning letters and prescription drug promotion letters.

Q.02

What should drug promotion teams change?

I still can't tell you what the Vectibix letter itself requires: neither FDA's site nor the warning letters I can search include it yet. FDA's recent promotion warning letters, though, keep raising the same problems. Promotion teams should check every channel for these six points.

  1. Give the risks the same weight as the benefits. This is the most common finding.

    • FDA objected to a social media post with no risk information at all [1], and to a podcast with none [2].
    • Paid search links were cited for having no risk information. Adding "Important Safety Info" or "Medication Guide" to the link text did not fix it [3].
    • In a 42-minute video, only four minutes covered risks, placed at the end, with nothing telling viewers where to find more [4][5].
    • One TV ad showed its risk information only after the screen faded to black [2]. In another, the risk statement was in small text at the bottom of the screen with poor contrast, competing with fast cuts, close-ups and rising music [6].

  2. Don't claim more than the study design can show. This matters most in oncology.

    • FDA said a single-arm study can't support claims about disease-free survival or other time-to-event results, so "it doesn't come back" and "cure" claims were not supported [2].
    • Claims that a drug works on its own were cited when it was approved only in combination with another treatment [2].
    • A sales aid that implied a survival (all-cause mortality) benefit the cited references didn't support was also cited [7].
    • Images can overstate efficacy too: an ad showing a patient shielded from "all the germs" was cited [6].

  3. State the full approved indication, including limits of use. Letters cited materials that left out the "in combination with" condition, the patient group, or the limitations of use [2][1].

  4. Don't suggest unapproved uses or routes of administration. FDA treated claims about other cancers, prevention, or injecting a drug labelled for bladder (intravesical) use only as evidence of new intended uses. The labelling has no adequate directions for those uses, which misbrands the drug [2].

  5. Treat executives, sales leaders and paid consultants as speaking for the company.

    • The CEO's personal Instagram post was treated as promotion [1].
    • So was a podcast featuring the executive chairman [2].
    • A TV special counted too, because it featured paid consultants and a senior sales executive [4].

  6. Submit every piece on Form FDA 2253 when it is first used. Letters cited failures under 21 CFR 314.81(b)(3)(i) for a podcast, an Instagram post, search links and a TV special [2][1][3][4].

Two process points:

  • Search links: the established (generic) name must appear prominently next to the brand name, including in paid search links [3].
  • Earlier FDA comments: repeat problems raise the stakes. FDA pointed to earlier untitled letters to ImmunityBio's subsidiary and an earlier warning letter to Sprout [2][1]. CSL Behring got a warning letter after it aired an ad without fully fixing the problems FDA's biologics advertising branch had raised on the storyboard [6].

What a letter would demand: a written response within 15 working days, a list of every other promotional piece making similar claims (with its 2253 submission date), and a plan to stop using them. FDA also asks for corrective messages sent to the same audiences, through the same media where possible, and generally for the same length of time and as often as the original. These messages must be free of promotional claims [2][3]. It's worth preparing that list of materials in advance.

Approach: I searched FDA's warning letters for Amgen, Vectibix and panitumumab and found none. I then read the promotion warning letters issued from 2023 to March 2026 by FDA's drug promotion office (OPDP), CDER and CBER. A further search of fda.gov also found no Vectibix warning letter; the only Vectibix result was a 2009 label.

Q.03